Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis, Multidrug-Resistant
Conditions
Tuberculosis, Multidrug-Resistant
Trial Timeline
Jun 7, 2022 → May 31, 2027
NCT ID
NCT03828201About Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid
Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid is a phase 2 stage product being developed by Novartis for Tuberculosis, Multidrug-Resistant. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03828201. Target conditions include Tuberculosis, Multidrug-Resistant.
What happened to similar drugs?
3 of 5 similar drugs in Tuberculosis, Multidrug-Resistant were approved
Approved (3) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03828201 | Phase 2 | Recruiting |
Competing Products
20 competing products in Tuberculosis, Multidrug-Resistant